Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

NCT04149821 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Terminated due to low accrual

Conditions

Chronic Lymphocytic Leukemia
CLL Progression
CLL/SLL

Interventions

DRUG: Umbralisib
DRUG: Ublituximab

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]